MiMedx Group, Inc. (MDXG)
| Market Cap | 1.02B |
| Revenue (ttm) | 309.02M |
| Net Income (ttm) | -2.54M |
| Shares Out | 116.38M |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | 31.84 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 526,307 |
| Open | 8.92 |
| Previous Close | 8.90 |
| Day's Range | 8.73 - 8.96 |
| 52-Week Range | 2.72 - 9.27 |
| Beta | 1.66 |
| Analysts | Strong Buy |
| Price Target | 11.67 (+33.07%) |
| Earnings Date | Oct 30, 2023 |
About MDXG
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of ch... [Read more]
Financial Performance
In 2022, MiMedx Group's revenue was $267.84 million, an increase of 3.57% compared to the previous year's $258.62 million. Losses were -$36.78 million, 124.0% more than in 2021.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for MDXG stock is "Strong Buy." The 12-month stock price forecast is $11.67, which is an increase of 33.07% from the latest price.
News
MiMedx reports US FDA warning letter for Axiofill, shares drop
MiMedx Group said on Friday it had received a warning letter from the U.S. Food and Drug Administration related to the classification of its placental-derived tissue product Axiofill, and its shares f...
MIMEDX Provides AXIOFILL® Update & Reiterates 2023 Full Year Net Sales and Fourth Quarter Adjusted EBITDA Margin Outlook
Receipt of FDA Warning Letter for AXIOFILL Classification; Not Related to Safety Request for Designation for AXIOFILL Submitted to FDA and Currently Under Review Reiterates Expectations for 2023 Net S...
MIMEDX Announces Conversion of Outstanding Series B Convertible Preferred Stock to Common Stock
MARIETTA, Ga., Dec. 28, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that its outstanding 95,000 shares of Series B Convertible Preferred Stoc...
MIMEDX to Participate in Upcoming Investor Conferences
MARIETTA, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following i...
MIMEDX to Highlight Published Data at SAWC Fall
MARIETTA, Ga., Nov. 02, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it will sponsor an Innovation Theater lunch symposium at the Symposium on...
MIMEDX Announces Third Quarter 2023 Operating and Financial Results
Third Consecutive Quarter of Net Sales Growth Exceeding 20% Over the Prior Year Period Raises Full-Year 2023 Net Sales Percentage Growth Outlook to the High Teens MARIETTA, Ga., Oct. 30, 2023 (GLOBE N...
MIMEDX Announces Second Quarter 2023 Operating and Financial Results
Records Second Quarter Net Sales of $81.3 Million; an Increase of 21.5% Over the Prior Year Period Increases Full-Year 2023 Guidance for Net Sales Growth Welcomes Highly Successful MedTech Executive a...
MIMEDX to Host Second Quarter 2023 Operating and Financial Results Conference Call on August 1
MARIETTA, Ga., July 18, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second qu...
MIMEDX Announces Favorable Ruling in Putative Securities Class Action Case
MARIETTA, Ga., July 11, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that the Eleventh Circuit Court of Appeals affirmed the dismissal of the ...
MIMEDX Appoints Doug Rice as Chief Financial Officer
MARIETTA, Ga., July 05, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has appointed Doug Rice as the Company's Chief Financial Officer,...
MIMEDX Announces Strategic Realignment: Increases Focus on Wound & Surgical Business, Expected to Significantly Improve Profitability
Suspending Current Activities Associated with Knee Osteoarthritis Program and Disbanding Regenerative Medicine Business Unit
MIMEDX Announces First Quarter 2023 Operating and Financial Results
First Quarter Net Sales of $71.7 Million Reflect an Increase of 21.7% Over the Prior Year Period
MIMEDX to Host First Quarter 2023 Operating and Financial Results Conference Call on May 2
MARIETTA, Ga., April 18, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that it will report operat...
MIMEDX Announces Chief Financial Officer Transition
Executive Search Underway Executive Search Underway
MIMEDX Comments on Recent Data Brief Published by Office of Inspector General
Company applauds the Office of Inspector General's (“OIG”) recommendation for the Centers for Medicare and Medicaid Services (“CMS”) to quickly address issues associated with Average Sales Price (“ASP...
MIMEDX Announces Fourth Quarter and Full Year 2022 Operating and Financial Results
Reports Highest Quarterly Net Sales Since the Fourth Quarter of 2019
MIMEDX Appoints Joseph H. Capper as Chief Executive Officer and Director
Highly experienced and accomplished three-time healthcare CEO with a proven track record of substantial value creation to lead MIMEDX
MIMEDX Confirms Fourth Quarter and Full Year 2022 Net Sales Expectations, Comments on Evolving Medicare Reimbursement Landscape and Provides Corporate Updates
Fourth quarter and full year 2022 net sales expected in the ranges of $73 million to $76 million and $266 million to $269 million, respectively
MIMEDX Announces Commercial Launch of EPIFIX® in Japan with Exclusive Distribution Agreement with GUNZE MEDICAL LIMITED
MIMEDX aligns with a leading distributor of wound care products in Japan to capitalize on first-mover advantage for EPIFIX
MIMEDX Announces Third Quarter 2022 Operating and Financial Results
Third Quarter Net Sales of $67.7 Million Reflect Growth of 7.3%
MIMEDX Announces Launch of AMNIOEFFECT™
New Product Enables Company to Target Additional Surgical Procedures and Deepen Market Penetration in the Growing $1B Surgical Recovery Market
MIMEDX EPIFIX® Receives Reimbursement Approval in Japan
Provides Favorable Access to a New $500 Million Market for the Treatment of Refractory Diabetic and Venous Ulcers for EPIFIX – the First and Only Amniotic Tissue Product Approved for Use in Japan
Regenerative Engineering Society Establishes Award in Honor of MIMEDX Board Member, Dr. Cato T. Laurencin
The Cato T. Laurencin Regenerative Engineering Founders' Award Promotes Advancement of Scientific Leadership and Research in the Field of Regenerative Engineering
MIMEDX to Present at the Canaccord Genuity 42nd Annual Growth Conference
MARIETTA, Ga., Aug. 04, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that senior management w...
MIMEDX to Host Second Quarter 2022 Operating and Financial Results Conference Call on August 3
MARIETTA, Ga., July 20, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report oper...